Editorial Comment
Drug-eluting or bare metal stents for diabetics: Clinical judgment still wins†
William B. Hillegass MD, MPH,
Corresponding Author
William B. Hillegass MD, MPH
University of Alabama at Birmingham, Birmingham, Alabama
Interventional Cardiovascular Section, FOT 907, 510 20th Street South, Birmingham, AL 35294Search for more papers by this authorWilliam B. Hillegass MD, MPH,
Corresponding Author
William B. Hillegass MD, MPH
University of Alabama at Birmingham, Birmingham, Alabama
Interventional Cardiovascular Section, FOT 907, 510 20th Street South, Birmingham, AL 35294Search for more papers by this authorFirst published: 29 September 2010
†
Conflict of interest: Nothing to report.
No abstract is available for this article.
REFERENCES
- 1 Schhen AJ,Warzee F,Legrand VMG. Drug-eluting stents: Meta-analysis in diabetic patients. Eur Heart J 2004; 25: 2167–2176.
- 2 Mahmud E,Bromberg-Marin G,Palakodeti V,Ang L,Creanga D,Demaria AN. Clinical efficacy of drug-eluting stents in diabetic patients: A meta-analysis. J Am Coll Cardiol 2008; 51: 2385–2395.
- 3 Chan C,Zambahari R,Kaul U,Lau CP,Whitworth H,Cohen S,Buchbinder M,DECODE Investigators. A randomized comparison of sirolimus-eluting versus bare metal stents in the treatment of diabetic patients with native coronary artery lesions: The DECODE study. Cathet Cardiovasc Diagn 2010; 72: 591–600.
- 4 Sabate M,Jiminez-Quevedo P,Angiolillo DJ,Gomez-Hospital JA,Alfonso F,Hernandez-Antolin R,Goicolea J,Banuelos C,Escaned J,Moreno R,Fernandez C,Fernandez-Aviles F,Macaya C, DIABETES Investigators. Randomized comparison of sirolimus eluting stent versus standard stent for percutaneous revascularization in diabetic patients: The Diabetes and Sirolimus Eluting Stent (DIABETES) trial. Circulation 2005; 112: 2175–2183.
- 5 Kirtane AJ,Gupta A,Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents: Comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009; 119: 3198–3206.
- 6 Machecourt J,Danchin N,Lablanche JM,Fauvel JM,Bonnet JL,Marliere S,Foote A,Quesada JL,Eltchaninoff H,Vanzetto G, EVASTENT Investigators. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: The EVASTENT matched-cohort registry. J Am Coll Cardiol 2007; 50: 501–508.
- 7 Ramanath VS,Brown JR,Malenka DJ,De Vries JT,Sidhu MS,Robb JF,Jayne JE,Hettleman, BD,Friedman BJ,Niles NW II,Kaplan AV,Thompson CA. Outcomes of diabetics receiving bare-metal stents versus drug-eluting stents. Cathet Cardiovasc Diagn, in press.
- 8 Austin PC. Some methods of propensity-score matching had superior performance to others: Results of an empirical investigation and Monte Carlo simulations. Biom J 2009; 51: 171–184.
- 9 Douglas PS,Brennan JM,Anstrom KJ, et al. Clinical effectiveness of coronary stents in elderly persons: Results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry. J Am Coll Cardiol 2009; 53: 1629–1641.
- 10 Stone GW,Rizvi A,Newman W,Mastali K,Wang JC,Caputo R,Doostzadeh J,Cao S,Simonton CA,Sudhir K,Lansky AJ,Cutlip DE,Kereiakes DJ, SPIRIT IV Investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010; 362: 1663–1674.
- 11 Kedhi E,Joesoef KS,McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): A randomized trial. Lancet 20; 375: 201–209.
- 12 Wiviott SD,Braunwald E,Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation 2008; 118: 1626–1636.
